ICER thresholds

Market Access

The ICER threshold increase is expected to allow an additional three to five medicines or indications each year to be recommended for NHS use.

News

In its third big licensing deal of the week, Eli Lilly has tapped RNA-editing specialist Ascidian for kidney disease therapies in a $1.9bn alliance.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.